Investigation and Control of Vancomycin-Intermediate and -Resistant Staphylococcus aureus: A Guide for Health Departments and Infection Control Personnel

摘要

This document provides guidance in conducting a public health evaluation for patients from whom vancomycin-intermediate S. aureus (VISA$ minimum inhibitory concentration (MIC) = 8 or 16 (micro)g/ml ) and vancomycin-resistant S. aureus (VRSA, vancomycin MIC greater than or equal to 32 (micro)g/ml) has been isolated or is suspected. The information reflects the experience gained from several field investigations and consultations for addressing issues pertaining to VISA/VRSA and other isolates with reduced susceptibility to vancomycin (minimum inhibitory concentration (MIC) greater than or equal to 4(micro)g/ml). Staphylococcus aureus is an important cause of healthcare-associated infections. The diseases associated with this organism range from mild skin and soft-tissue infections to potentially fatal systemic illnesses such as endocarditis and toxic-shock syndrome. S. aureus is a common pathogen that affects individuals across the age spectrum.